Home / Conditions / Prostate Cancer
Prostate Cancer: when insurers say no, reviewers often say yes
In 456 published external-review decisions involving prostate cancer, independent physician reviewers overturned the insurer’s denial 32.9% of the time.
Published decisions
456
2001–2026
Overturned
32.9%
150 denials reversed
Most-fought treatments for prostate cancer
What insurers denied — and how those fights ended.
| Treatment | Decisions | Overturned |
|---|---|---|
| Proton Beam Radiation Therapy | 69 | 5.8% |
| Proton Beam Therapy | 53 | 7.5% |
| Intensity Modulated Radiation Therapy | 22 | 63.6% |
| Hifu | 17 | 35.3% |
| Oncotype Dx Prostate Cancer Assay | 12 | 75% |
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for prostate cancer was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.